Expand DYN Menu
DYN MENU

DYN Latest Press Releases

-- December 23, 2025 --

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors Globe Newswire 7:30 AM

-- December 11, 2025 --

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares Globe Newswire 4:05 PM

-- December 9, 2025 --

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock Globe Newswire 9:42 PM

-- December 8, 2025 --

Dyne Therapeutics Announces Proposed Public Offering of Common Stock Globe Newswire 4:02 PM
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Globe Newswire 6:30 AM

-- December 7, 2025 --

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET Globe Newswire 11:00 AM

-- November 5, 2025 --

Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights Globe Newswire 4:10 PM

-- November 3, 2025 --

Dyne Therapeutics to Present at Upcoming Investor Conferences Globe Newswire 7:30 AM

-- October 6, 2025 --

Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) Globe Newswire 6:01 PM

-- October 2, 2025 --

Dyne Therapeutics Appoints Brian Posner to its Board of Directors Globe Newswire 4:05 PM

-- August 27, 2025 --

Dyne Therapeutics to Present at Upcoming Investor Conferences Globe Newswire 7:30 AM

-- August 16, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN PRNewswire 10:00 AM

-- August 11, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN PRNewswire 10:00 AM

-- August 9, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN Globe Newswire 12:38 PM

-- August 6, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN PRNewswire 10:00 AM

-- August 5, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Dyne Therapeutics, Inc. - DYN Globe Newswire 10:00 AM

-- August 4, 2025 --

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) Globe Newswire 7:30 AM

-- August 1, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN Globe Newswire 10:00 AM

-- July 31, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN PRNewswire 10:00 AM
Market Data Delayed 15 Minutes